ZIM Laboratories Limited

NSE ZIMLAB.NS

ZIM Laboratories Limited Operating Cash Flow for the year ending March 31, 2024: USD 1.95 M

ZIM Laboratories Limited Operating Cash Flow is USD 1.95 M for the year ending March 31, 2024, a -57.25% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

ZIM Laboratories Limited Operating Cash Flow for the year ending March 31, 2023 was USD 4.56 M, a -29.56% change year over year.
ZIM Laboratories Limited Operating Cash Flow for the year ending March 31, 2022 was USD 6.48 M, a 48.98% change year over year.
ZIM Laboratories Limited Operating Cash Flow for the year ending March 31, 2021 was USD 4.35 M, a 49.58% change year over year.
ZIM Laboratories Limited Operating Cash Flow for the year ending March 31, 2020 was USD 2.91 M, a -42.04% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

NSE: ZIMLAB.NS

ZIM Laboratories Limited

CEO	Dr. Chandrashekhar Mainde
IPO Date	Nov. 25, 2022
Location	India
Headquarters	Sadoday Gyan
Employees	556
Sector	Healthcare
Industries Pharmaceuticals Clinical Trials Drugstores & Retail Pharmacies Fertilizers

Description

ZIM Laboratories Limited develops, manufactures, and supplies pharmaceutical formulation and pre formulation ingredients in India and internationally. The company provides technology-based drug delivery solutions and non-infringing proprietary manufacturing processes for generic pharmaceutical products in semi-finished and finished categories/formulations, such as granules, pellets, taste masked powders, suspensions, tablets, capsules, and oral thin films. It serves therapeutic areas, such as urology, gastroenterology, cardiology, and anticoagulants, as well as antibiotics and anti-infectives, NSAIDs/pain analgesics, and vitamins and supplements. ZIM Laboratories Limited was incorporated in 1984 and is based in Nagpur, India.

Key trends

Past 5 years